Deucravacitinib Superior to Placebo, Apremilast in Phase 3 Plaque Psoriasis Trials

摘要

Deucravacitinib showed significant improvement in plaque psoriasis compared with both placebo and apremilast, according to two studies."Deucravacitinib is a novel, oral, selective TYK2 inhibitor, which is unique in that it binds to the TYK2 regulatory domain with high selectivity," April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, said.The phase 3 POETYK PSO-1 and POETYK PSO-2 trials, which were identical in design through week 24, randomly assigned patients 2:2:1 to receive once-daily deucravacitinib 6 mg, placebo or twice-daily apremilast 30 mg.